Eyenovia, Inc.

EYEN

US30234E2037

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 04:00:00 2025-06-16 pm EDT			5-day change	1st Jan Change
2.970 ^USD	+21.72%		-39.14%	-74.57%

Jun. 09	Formosa Pharmaceuticals Ends Exclusive Licensing Deal With Eyenovia	MT
Jun. 06	Top Premarket Gainers	MT

Eyenovia, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025

Published on 05/19/2025 at 17:02

Eyenovia, Inc. reported earnings results for the first quarter ended March 31, 2025. For the first quarter, the company reported sales was USD 0.01472 million compared to USD 0.004993 million a year ago. Net loss was USD 3.48 million compared to USD 10.92 million a year ago.

Basic loss per share from continuing operations was USD 1.59 compared to USD 18.75 a year ago.

Latest news about Eyenovia, Inc.

Formosa Pharmaceuticals Ends Exclusive Licensing Deal With Eyenovia	Jun. 09	MT
Top Premarket Gainers	Jun. 06	MT
Eyenovia On May 30, Enters Third Amendment To Loan And Security Agreement - SEC Filing	Jun. 05	RE
Eyenovia, Inc. Enters into the Third Amendment to the Supplement to That Certain Loan and Security Agreement	Jun. 05	CI
Eyenovia Provides Updates On Potential Merger With Betaliq And Development Of The Optejet User Filled Device (Ufd), And Reports First Quarter 2025 Financial Results	May. 19	RE
Eyenovia, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025	May. 19	CI
Eyenovia, Inc. Reports Earnings Results for the Full Year Ended December 31, 2024	Apr. 15	CI
Eyenovia, Inc. Auditor Raises 'Going Concern' Doubt	Apr. 14	CI
Eyenovia, Inc. Provides Development Update on Optejet User Filled Device	Apr. 10	CI
Eyenovia Files For Non-Timely 10-K - SEC Filing	Mar. 31	RE
Eyenovia Enters Into Non-Binding Letter Of Intent To Effect Reverse Merger With Betaliq	Mar. 20	RE
Betaliq, Inc. entered into a non-binding letter of intent to acquire Eyenovia, Inc. in a reverse merger transaction.	Mar. 19	CI
Eyenovia, Inc. Enters into the Second Amendment to the Supplement to that Certain Loan and Security Agreement	Feb. 24	CI
Eyenovia, Inc. Announces Progress on Next-Generation User-Filled Optejet Dispensing Device	Feb. 05	CI
Top Midday Decliners	Jan. 29	MT
Eyenovia Hires Chardan as Financial Adviser to Review Strategic Options	Jan. 06	MT
Eyenovia Engages Chardan as Advisor for Review of Strategic Alternatives	Jan. 06	CI
Eyenovia Signs $1.9 Million Registered Direct Offering	Dec. 06	MT
Eyenovia Continues to Evaluate Broad Range of Strategic Alternatives to Maximize Stakeholder Value	Nov. 22	CI
Sector Update: Health Care Stocks Advance Premarket Friday	Nov. 22	MT
Eyenovia Says Avenue Capital Agrees to Potential Loan Restructuring; Shares Up Pre-Bell	Nov. 22	MT
Sector Update: Health Care Stocks Advance Late Afternoon	Nov. 20	MT
Sector Update: Health Care Stocks Advance Wednesday Afternoon	Nov. 20	MT
Sector Update: Health Care	Nov. 20	MT
Eyenovia Stock Plunges After Firm Reports Potential Restructuring Talks	Nov. 20	MT

Chart Eyenovia, Inc.

Duration

Period

EYEN: Dynamic Chart

Company Profile

Eyenovia, Inc. is a commercial-stage ophthalmic pharmaceutical technology company developing a pipeline of microdose array print therapeutics based on its Optejet platform. It is focused on the commercialization of Mydcombi (tropicamide+phenylephrine ophthalmic spray) for mydriasis, as well as clobetasol propionate ophthalmic suspension 0.05% to reduce pain and inflammation following ocular surgery. Its product line includes Mydcombi, clobetasol propionate, and therapeutic programs, MicroPine and MicroLine. Mydcombi is its fixed combination formulation of tropicamide-phenylephrine for inducing mydriasis for diagnostic procedures and in conditions where short-term pupil dilation is desired. MicroPine is its topical therapy for the treatment of progressive myopia, a disease associated with pathologic axial elongation of the eye and sclero-retinal stretching. MicroLine is its investigational pharmacologic treatment for presbyopia, a non-preventable, age-related hardening of the lens.

Employees

Sector

Pharmaceuticals

Calendar

Aug. 05 - Q2 2025 Earnings Release (Projected)

More about the company